Treatment of Atrophic Gastritis
Etiology-Based Treatment Approach
- The American Gastroenterological Association recommends that all patients with atrophic gastritis must be assessed for H. pylori infection using non-serological testing modalities 1, 2
- If H. pylori positive, eradication therapy should be administered promptly, as recommended by the American Gastroenterological Association 2, 3
- Successful eradication must be confirmed using non-serological testing methods, according to the American Gastroenterological Association 2, 3
- H. pylori eradication may modify the natural history of atrophy, though it has less effect on intestinal metaplasia, as noted by the American Gastroenterological Association 3, 4
- Confirm diagnosis of autoimmune atrophic gastritis through antiparietal cell antibodies and anti-intrinsic factor antibodies, as recommended by the American Gastroenterological Association 1, 5
- Screen for associated autoimmune disorders, particularly autoimmune thyroid disease, in patients with autoimmune atrophic gastritis, according to the American Gastroenterological Association 4, 5
Management of Micronutrient Deficiencies
- Evaluate all patients with atrophic gastritis for iron and vitamin B-12 deficiencies, especially if corpus-predominant, as recommended by the American Gastroenterological Association 4, 5
- Iron deficiency is common (up to 50% of patients with corpus-predominant atrophic gastritis) and often presents earlier than B-12 deficiency, according to the American Gastroenterological Association 5
Surveillance for Neoplastic Lesions
- Consider surveillance endoscopy every 3 years for patients with advanced atrophic gastritis, based on anatomic extent and histologic grade, as recommended by the American Gastroenterological Association 1, 3
- Patients with a new diagnosis of pernicious anemia should undergo endoscopy to confirm corpus-predominant atrophic gastritis and rule out gastric neoplasia, according to the American Gastroenterological Association 2, 6
- Screen for type 1 gastric neuroendocrine tumors with upper endoscopy in patients with autoimmune atrophic gastritis, as recommended by the American Gastroenterological Association 6, 3
- Small neuroendocrine tumors (<1 cm) should be removed endoscopically, according to the American Gastroenterological Association 4, 5
- Consider surveillance endoscopy every 1-2 years depending on the burden of neuroendocrine tumors in patients with autoimmune atrophic gastritis, as recommended by the American Gastroenterological Association 4, 5
- For gastric NETs >1-2 cm, consider endoscopic ultrasound to assess invasion depth and presence of local metastasis, according to the American Gastroenterological Association 5
- Surgical resection is appropriate for NETs >2 cm, with invasion past submucosa, or with evidence of lymph node metastasis, as recommended by the American Gastroenterological Association 5
Management of Coexisting Conditions
- In patients with autoimmune gastritis, screen for autoimmune thyroid disease, as recommended by the American Gastroenterological Association 4, 5
- Consider evaluating for other associated autoimmune diseases if clinically indicated in patients with autoimmune atrophic gastritis, according to the American Gastroenterological Association 4
Pitfalls and Caveats
- Atrophic gastritis is often underdiagnosed due to subtle endoscopic features and inconsistent histopathological reporting, as noted by the American Gastroenterological Association 1
- Ensure proper biopsy sampling (minimum from body and antrum/incisura in separate jars) for accurate diagnosis and risk stratification, as recommended by the American Gastroenterological Association 1, 6
- The risk of gastric adenocarcinoma might be highest within the first year of pernicious anemia diagnosis, warranting prompt endoscopic evaluation, according to the American Gastroenterological Association 4
Guideline Recommendations for Management of Atrophic Gastritis
Diagnostic Work‑up
- Endoscopic assessment should look for pale mucosa, prominent submucosal vessels, loss of gastric folds, and, when intestinal metaplasia is present, light‑blue crests and white opaque fields. 7, 8
- Obtain separate biopsies from the gastric body and the antrum/incisura, placing them in individually labeled jars to allow accurate histopathologic risk stratification. 7, 8
- Targeted biopsies must be taken from any additional mucosal abnormalities identified during endoscopy. 7, 8
- When histology suggests autoimmune (corpus‑predominant) gastritis, test for antiparietal cell antibodies and anti‑intrinsic factor antibodies. 7, 8
- All patients with autoimmune gastritis should be screened for autoimmune thyroid disease because concomitant autoimmune disorders are common. 7, 8
H. pylori Assessment and Eradication
- All patients with atrophic gastritis require H. pylori testing using non‑serologic methods (e.g., urea breath test, stool antigen) because serology remains positive after eradication. 7, 8
- If H. pylori is detected, eradication therapy should be initiated promptly. 7, 8
- Successful eradication must be confirmed with a repeat non‑serologic test. 7, 8
Micronutrient Deficiency Management
- Screen every patient with atrophic gastritis for iron and vitamin B12 deficiencies, giving particular attention to those with corpus‑predominant atrophy. 7, 8
- Recognize pernicious anemia as a late‑stage manifestation characterized by vitamin B12 deficiency and macrocytic anemia. 7, 8
- In newly diagnosed pernicious anemia without a recent endoscopy, perform an upper endoscopy with topographic biopsies to confirm corpus‑predominant atrophy and exclude gastric neoplasia. 7, 8
Endoscopic Surveillance Strategy
- Patients with advanced atrophic gastritis (extensive anatomic distribution and high histologic grade) should undergo surveillance endoscopy every 3 years. 7, 8
- For autoimmune gastritis patients who develop gastric neuroendocrine tumors (NETs), schedule surveillance endoscopy every 1–2 years, adjusting the interval according to NET burden. 7, 8